# Curestream

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/curestream

- Industry: Healthcare
- Headquarters: Daegu, South Korea
- Website: www.curestream.co.kr/
- Total disclosed funding: $7.9M
- Latest round: Series A (May 7, 2025)
- Investors on record: 7

## About

Based in South Korea, Curestream is a medical device company focused on innovative diabetes management solutions, developing advanced technologies to improve the quality of life for diabetes patients.Curestream, founded in 2019 and headquartered in Daegu, South Korea, specializes in advanced medical solutions for diabetes management. The company has received KRW 11 billion in funding during its Series A round from notable investors such as Devsisters Ventures and Innopolis Partners. Curestream's latest funding event occurred on May 7, 2025, providing significant support for its ongoing initiatives. The founder's history includes previous entrepreneurial experience, although details on other companies are not disclosed.Curestream specializes in developing advanced medical solutions for diabetes management, including a fully autonomous artificial pancreas system that uses reinforcement learning algorithms for insulin delivery. Their modular, wearable insulin pump aims to address economic challenges faced by diabetes patients. The company serves approximately 3.2 million diabetes patients in South Korea, offering products that require consistent insulin administration.Curestream generates revenue through direct sales of its medical devices to consumers and healthcare providers, employing a direct-to-consumer business model. Customers purchase the modular insulin pump along with the intelligent insulin delivery algorithm, facilitating effective diabetes management. Revenue consists of one-time purchases of medical devices and potentially includes additional service offerings, although specific pricing structures are not disclosed.Curestream plans to leverage the KRW 11 billion raised in the Series A funding round to enhance its product offerings and expand its market presence. Future initiatives include the development of new products aimed at further improving diabetes management solutions. The company is also focused on expanding into international markets, with targeted regions and timelines to be determined as part of its strategic growth.

## Funding rounds

- Series A, May 7, 2025, $7.9M — Innopolis Partners, WOORI Venture Partners, Smilegate Investment, Devsisters Ventures, Korea Credit Guarantee Fund, We Ventures, Vivid Investment

## Investors

- Innopolis Partners (https://capitalatlas.ai/funds/innopolis-partners) — Series A
- WOORI Venture Partners (https://capitalatlas.ai/funds/woori-venture-partners) — Series A
- Smilegate Investment (https://capitalatlas.ai/funds/smilegate-investment) — Series A
- Devsisters Ventures (https://capitalatlas.ai/funds/devsisters-ventures) — Series A
- Korea Credit Guarantee Fund — Series A
- We Ventures — Series A
- Vivid Investment (https://capitalatlas.ai/funds/vivid-investment) — Series A